The t(4;14)(p16.3;q32) chromosomal translocation occurs in approximately 20% of multiple myelomas (MM) and leads to the apparent deregulation of two genes located on 4p16.3: the ®broblast growth factor receptor 3 (FGFR3) and the putative transcription factor WHSC1/ MMSET. Interestingly, FGFR3 mutations known to be associated with autosomal dominant human skeletal disorders have also been found in some MM cell lines with t(4;14) but their pathogenetic role in MM is still controversial. Since cell lines may represent useful models for investigating the eects of deregulated FGFR3 mutants in MM, we analysed the expression, activation, signaling pathways and oncogenic potential of three mutants identi®ed so far: the Y373C and K650E in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutation here identi®ed in the KMS-18 cell line. All of the cell lines present a heterozygous FGFR3 gene mutation and transcribe the mutated allele; unlike KMS-11 and OPM-2 (which express the IIIc isoform), the KMS-18 cell line expresses prevalently the isoform IIIb. We demonstrated that, under serum-starved conditions, KMS-11 and OPM-2 cells express appreciable levels of phosphorylated FGFR3 mutants indicating a constitutive activation of the Y373C and K650E receptors; the addition of the aFGF ligand further increased the level of receptor phosphorylation. Conversely, the FGFR3 mutant in KMS-18 does not seem to be constitutively activated since it was phosphorylated only in the presence of the ligand. In all three MM cell lines, ligand-stimulated FGFR3 mutants activated the MAP kinase signaling pathway but did not apparently involve either the STAT1 or STAT3 cascades. However, when transfected in 293T cells, G384D, like Y373C and K650E, was capable of activating MAPK, STAT1 and STAT3 under serum-starved condition. Finally, a focus formation assay of NIH3T3 cells transfected with FGFR3-expressing plasmid vectors showed that Y373C and K650E (albeit at dierent levels) but not G384D or the wild-type receptor, can induce transformed foci. Overall, our results support the idea that FGFR3 mutations are graded in terms of their activation capability, thus suggesting that they may play a critical role in the tumor progression of MM patients with t(4;14). Oncogene (2001) 20, 3553 ± 3562.
Introduction
Fibroblast growth-factor receptor 3 (FGFR3) belongs to a class of transmembrane tyrosine kinase receptors (FGFR1 ± 4) involved in signal transduction regulating cell growth and dierentiation in many tissue types (Basilico and Moscatelli, 1992; Johnson and Williams, 1993) . FGFR3 contains three glycosylated extracellular immunoglobulin-like domains (Ig-like), a transmembrane domain (TM), and a split intracellular tyrosinekinase domain. Ligand binding induces receptor homoand heterodimerization, which lead to the phosphorylation of the kinase-domain. Two distinct isoforms (IIIb or IIIc) are generated by alternative exon splicing encoding the C-terminal half of the third Ig-like domain, which have dierent ligand anity. Mutations in the FGFR3 gene cause a variety of genetic skeletal dysplasias such as achondroplasia, hypochondroplasia or thanatophoric dysplasia type I (TDI) and II (TDII) (for review: Muenke and Schell, 1997; Webster and Donoghue, 1997a) . There is evidence that these mutations trigger the constitutive activation of the receptor that plays a critical role in the control of endochondral ossi®cation (Deng et al., 1996) .
We and others have recently shown that the FGFR3 gene is involved in human cancer by identifying a novel t(4;14)(p16.3;q32) translocation in multiple myeloma, a malignant proliferation of bone marrow plasma cells (Chesi et al., 1997; Richelda et al., 1997) . 4p16.3 breakpoints occur approximately 50 ± 120 kb centromeric to the FGFR3 gene (Thompson et al., 1991) and within the 5' region of the novel putative transcription factor WHSC1/MMSET (Stec et al., 1998; Chesi et al., 1998) , thus leading to the overexpression of the two genes and the generation of IGH/MMSET hybrid transcripts. We have recently demonstrated by molecular and FISH analyses that this lesion occurs in about 20% of MM tumors (Finelli et al., 1999; Malgeri et al., 2000) . Interestingly, FGFR3 gene mutations associated with autosomal human skeletal disorders, have also been identi®ed in some MMs with t(4;14): speci®cally, the mutation Y373C (Rousseau et al., 1996) in the KMS-11 MM cell line (Chesi et al., 1997; Richelda et al., 1997) ; K650E (Tavormina et al., 1995) in the OPM-2 cell line (Chesi et al., 1997) ; and K650M (Francomano, 1996) in a primary MM tumor (Chesi et al., 1997) . More recently, activating FGFR3 mutations have been reported in a large fraction of bladder and cervix carcinomas, which suggests that the receptor plays an oncogenic role in these neoplasias (Cappellen et al., 1999) .
The pathogenetic role of FGFR3 mutations in MM is still controversial. Although our previous work indicated that these events occur rarely in primary MM tumors (Fracchiolla et al., 1998) , the presence of mutations in MM cell lines suggests that they may play a role in the tumor progression of MM patients with t(4;14). The MM cell lines expressing deregulated FGFR3 mutants may therefore represent valid tools for investigating the eects of the altered receptor in MM. We analysed the expression, activation, signaling pathways and oncogenic potential of three FGFR3 mutants so far identi®ed in MM cell lines with t(4;14): the Y373C and K650E previously reported in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D identi®ed in our laboratory from the recently established KMS-18 cell line (Otsuki et al., 1998) .
Results

Expression of FGFR3 mutants in MM cell lines with the t(4;14) translocation
We evaluated the FGFR3 expression in four MM cell lines with t(4;14): KMS-11, OPM-2, NCI-H929 and the recently established KMS-18 (Otsuki et al., 1998) . The 4p16.3 breakpoint in the KMS-18 cell line was found to occur within intron 3 of the MMSET gene ( Figure  1a ; Ronchetti et al., 2001) . As previously reported KMS-11, OPM-2 but not NCI-H929 are associated with a speci®c FGFR3 mutation (Chesi et al., 1997; Richelda et al., 1997) . We investigated the presence of FGFR3 mutations in KMS-18 by means of PCR/SSCP and sequencing analysis as described by Fracchiolla et al. (1998) . These analyses revealed a nucleotide change (G to A transition) at the second base pair of codon 382 in the TM domain of FGFR3 isoform IIIc (FGFR3-IIIc), which corresponds to codon 384 of isoform IIIb (FGFR3-IIIb) that is two amino acids longer. This mutation leads to a non-conservative amino acid substitution Gly-Asp ( Figure 1b,c) ; to the best of our knowledge, such a mutation has not been previously reported in skeletal disorders, multiple myeloma, epithelial cancers or a signi®cative panel of normal individuals.
Northern blot analysis showed dierent levels of FGFR3 transcripts in these cell lines (Figure 2a) , with those in NCI-H929 being lower than those observed in the cell lines carrying mutated FGFR3s; no expression was detectable in U266, which is negative for t(4;14). This pattern was con®rmed by Western blot analysis (Figure 2b ) which detected faint levels of FGFR3 in NCI-H929. Interestingly, when used on KMS-18 cells, this assay showed FGFR3 forms with an apparently lower molecular weight; on the basis of previous evidence (Kanai et al., 1997) , this ®nding strongly suggested that KMS-18 may express the FGFR3-IIIb. In order to investigate this point further, we performed an RT ± PCR analysis using primers amplifying both the FGFR3-IIIc and -IIIb (see scheme in Figure 2c ) and discriminated the two variants by digesting the ampli®ed fragments with speci®c restriction enzymes as previously described (Murgue et al., 1994) . These data con®rmed that, unlike the other cell lines expressing the FGFR3-IIIc, KMS-18 cells mainly transcribe the FGFR3-IIIb and that their expression of FGFR3-IIIc is much less (Figure 2c ). It seems that, under our experimental conditions, the expression of the FGFR3-IIIc is undetectable by Western blot and so we will refer to the mutation in KMS-18 as G384D. Finally, the sequencing of the RT ± PCR ampli®ed fragments speci®c for the IIIb and IIIc isoforms indicated that, like KMS-11 and OPM-2 cell lines (Chesi et al., 1997; Richelda et al., 1997) , KMS-18 cells speci®cally overexpressed the mutated allele (data not shown).
Subcellular localization of overexpressed FGFR3 mutants in MM cell lines
The subcellular localization of the mutated FGFR3 protein overexpressed in MM cell lines was analysed by immuno¯uorescence analysis using an antibody raised against its C-terminus. As shown in Figure 3 , the KMS-11, OPM-2 and KMS-18 cell lines displayed intense cytoplasmic staining possibly associated with the secretory pathway; furthermore, perinuclear staining was also observed. The results in NCI-H929 cells (data not shown) were similar to those found in the negative control U266, thus con®rming their low level of FGFR3 expression.
Activation of mutated FGFR3 receptors in MM cell lines with t(4;14)
Previous studies have demonstrated that Y373C and K650E mutations in patients aected by skeletal disorders lead to constitutive phosphorylation and ligand-independent activation (Webster and Donoghue, 1997b; d'Avis et al., 1998) . Since this type of information was not available in relation to MM cell lines, we investigated the levels of receptor autophosphorylation and its response to the aFGF ligand in the KMS-11, OPM-2 and KMS-18 cell lines ( Figure  4a ). After serum starvation and in the absence of the aFGF ligand, FGFR3 phosphorylation was observed in KMS-11 and OPM-2, but not in KMS-18 cells, thus con®rming previous evidence concerning Y373C and K650E mutations in transfection experiments (Webster and Donoghue, 1997b; d'Avis et al., 1998) and suggesting that the G384D mutation in the KMS-18 cell line is not itself capable of activating the receptor. However, the FGFR3 in KMS-18 cells is responsive to the ligand in a dose-dependent manner. It is interesting to note that FGFR3 phosphorylation was further induced in the KMS-11 and OPM-2 cell lines by the presence of the aFGF ligand, which suggests that the Y373C and K650E mutations produce an activated receptor that is partially ligand-independent. Finally, we demonstrated that suramin (a competitor of the FGFs binding to FGFRs) inhibited ligand-dependent receptor phosphorylation in all of the cell lines when stimulated with aFGF, whereas it did not abolish the constitutive receptor phosphorylation of KMS-11 and OPM-2, thus suggesting that this is a consequence of the activating eect of the mutations rather than an autocrine loop (Figure 4a ).
Since various pathways (such as those involving MAPK and STATs) seem to mediate FGFR3 activation in dierent cell systems (Legeai-Mallet et al., 1998; Raoni et al., 1998; Johnson et al., 1998; CatlettFalcone et al., 1999; Hart et al., 2000;  for review see Kannan and Givol, 2000) , we analysed the downstream eects of FGFR3 expression in our MM cell lines. Using an in vivo phosphorylation assay, we evaluated the activation of MAPK, STAT1 and STAT3. All of the cell lines showed ERK1 and ERK2 phosphorylation even under serum-starved conditions, and the addition of the aFGF ligand appreciably increased phosphorylation levels ( Figure 4b ). We did not detect STAT1 phosphorylation in any of the cell lines under starved or stimulated conditions. STAT3 was found phosphorylated only in the KMS-11 cell line but no modulation in response to aFGF was observed; no induction of STAT3 phosphorylation was observed in (Figure 4b ). Our study did not include the deregulated wild-type receptor in NCI-H929 as a control because its expression is barely detectable by Western blotting. To address this point, we stably transfected the U266 cell line, which is negative for t(4;14) and does not express FGFR3, with plasmid vectors containing wild-type or Y373C FGFR3. The Western blot levels of FGFR3 expression in both the U266 wt and U266 Y373C cell populations were comparable with those in KMS-18 (data not shown). As shown in Figure 5a , FGFR3-wt is phosphorylated only in the presence of the ligand, whereas Y373C FGFR3 is constitutively activated in serum-starved cells, and further inducible by aFGF. The analysis of MAPK activation shows that the ERK1 and ERK2 phosphorylation in starved U266 wt and U266 Y373C cells appreciably increases following the addition of the ligand. Finally, STAT3 phosphorylation was not observed in either starved or stimulated U266 wt and U266 Y373C cells, and STAT1 was found to be phosphorylated in the absence of aFGF and was not further induced by the ligand (Figure 5b ).
Activity of FGFR3 mutants in 293T cells
To characterize the novel G384D mutation further, we investigated 293T cells transiently transfected with vectors expressing the wild-type or mutated FGFR3 receptors, including G384D-IIIb FGFR3 and G382D-IIIc FGFR3. In particular, we analysed the levels of MAPK, STAT1 and STAT3 expression and phosphorylation ( Figure 6 ). The transfected cells were starved and then analysed for FGFR3 expression; as shown in Figure 6a , comparably high levels of wild-type or mutated receptors were found. MAPK, STAT3 and STAT1 phosphorylation was observed in all of the cells transfected with the dierent mutated receptors ( Figure  6b ). These results indicate that, like Y373C and K650E, the novel G384D mutation is able to activate transduction signal cascades in the absence of ligand induction. This ®nding is not related to the high expression obtained in the transfected 293T cells because neither STAT1 nor STAT3 and only very low levels of MAPK phosphorylation, were observed in the cells expressing wild-type FGFR3.
Focus formation assay
The data concerning the oncogenic potential of wild type or mutated FGFR3 genes are still controversial. We performed a transformation assay of NIH3T3 cells transfected with plasmid vectors expressing wild-type or mutated FGFR3 cDNAs speci®c for the mutations associated with the MM cell lines. The novel mutation found in the KMS-18 cell line was analysed in both the IIIb and IIIc isoforms of the receptor. The results of three independent transfection experiments (each in Table 1 . Under our experimental conditions, mutations Y373C and K650E induce the formation of foci: the Y373C mutation had stronger transforming activity than K650E, but the degree of foci formation was less than that observed with the c-trk oncogene used as a positive control (Greco et al., 1995) . The morphology of the transformed cells is shown in Figure 7 . Western blot analyses of ®ve transformed foci isolated for each transforming construct revealed high levels of exogenous FGFR3 expression (see representative examples in Figure 7d ). Conversely, the wild-type receptor and the two isoforms respectively expressing the G384D and G382D mutations did not seem to be able to induce transformed foci.
Discussion
We investigated the expression, subcellular localization, activation, signaling pathways and oncogenic potential of three FGFR3 mutants so far identi®ed in MM cell lines bearing the t(4;14)(p16.3;q32) translocation: the Y373C and K650E mutants previously reported in the KMS-11 and OPM-2 cell lines respectively, and the novel G384D mutant identi®ed in our laboratory from the recently established KMS-18 cell line. Our data may provide some insights into the pathogenetic role of FGFR3 in MM. We found that KMS-18 has a monoallelic FGFR3 mutation involving the transmembrane domain of the gene and expresses only the mutated allele. These ®ndings are similar to those observed in the KMS-11 and OPM-2 cell lines (Chesi et al., 1997; Richelda et al., 1997) , but indicate two substantial dierences: KMS-18 prevalently expresses FGFR3-IIIb and harbors a G384D mutation (G382D in FGFR3-IIIc) which, to the best of our knowledge, has never been found in patients with skeletal disorders, multiple myelomas, or bladder or cervix carcinomas. The FGFR3-IIIb is generally expressed in cell types of epithelial origin but not in those of mesenchimal origin (such as hematopoietic cells). It has been previously reported that ®broblasts may show a mixture of IIIb and IIIc transcripts (Scotet and Houssaint, 1995) , and so this ®nding and our present data suggest that the choice of alternative isoforms in cells of mesenchimal origin is not strictly tissue-speci®c. It is conceivable that the G384D mutation is not a genetic polymorphism since we did not ®nd it in the PCR ± SSCP analyses of the TM domain of 80 MM patients and 100 normal controls (Fracchiolla et al., 1998) , nor has it been reported in other disorders associated with FGFR3 mutations (Muenke and Schell, 1997) . Interestingly, the G384D mutation occurs within a pentameric consensus region (Stenberg and Gullick, 1990 ) that is highly conserved in the TM domains of tyrosine kinase receptors (aa 379 ± 384 in FGFR3-IIIb), a sequence that is thought to play an important role in receptor dimerization on the basis of experimental evidences coming from studies of the mutant V664E Neu receptor. In particular, the substitution of the corresponding glycine with larger side chain residues in position 665 of Neu has been shown to aect receptor activation and its transforming ability (Lofts et al., 1993) . In KMS-18, the substitution of glycine with aspartic acid (a bulky chain residue) at codon 384 of FGFR3 does not seem to aect receptor activity nor induce its activation (see below).
The FGFR3 mutants investigated in this study have a cytoplasmic location possibly associated with the secretory pathway. Furthermore, a perinuclear localization similar to the pattern described in cultured and in vivo chondrocytes taken from the cartilage growth plates of TD patients, was also observed in our MM cell lines. It has been suggested that the presence of activating FGFR3 mutations in TD cells may trigger the translocation of the receptor from the cell surface to the perinuclear region (Legeai-Mallet et al., 1998). Moreover, there is evidence showing the perinuclear localization of FGFR1 in various cell types stimulated with FGFs, as well as the nuclear localization of a truncated form of FGFR3 in breast epithelial cells (Johnston et al., 1995) .
Our data indicate that deregulated FGFR3 mutants in KMS-11 and OPM-2 cells are phosphorylated under serum-deprived conditions, thus con®rming that these two mutations are capable of inducing constitutive receptor activation as has been observed in various cell types transfected with FGFR3 constructs (Naski et al., 1996; Webster et al., 1996; Webster and Donoghue, 1997b; Li et al., 1997) . These data are supported by our analysis of U266 transfected cells expressing wildtype or Y373C FGFR3, which showed that only the mutated receptor is phosphorylated in the absence of the ligand. Furthermore, we found that the respective Figure 4 FGFR3 mutants activity in the KMS-18, OPM-2 and KMS-11 MM cell lines. The cells were starved for 48 h, and then supplemented with 10 ng/ml aFGF, 100 ng/ml aFGF, 100 mg/ml suramin or suramin plus 100 ng/ml aFGF. (a) The cell lysates (4 mg total proteins for KMS-18, 2.5 mg for OPM-2 and 1 mg for KMS-11) were immunoprecipitated with FGFR3 antiserum and immunoblotted with phosphotyrosine antiserum; the phosphorylated receptor band at 135 kD is indicated. Below, the level of FGFR3 expression on the same ®lters was evaluated using FGFR3 antiserum; the molecular weight of the two dierent glycosylated forms of the FGFR3 receptor is indicated in kD. (b) Western blot analysis of 100 mg total proteins with speci®c antisera (from the top): MAP-phosphorylated (P-MAPK) antiserum or MAPK antiserum recognizing p44 and p42 (ERK1 and ERK2) proteins, STAT3-phosphorylated (P-STAT3) antiserum or STAT3 antiserum, STAT1-phosphorylated (P-STAT1) antiserum or STAT1 antiserum Activity of FGFR3 mutants in multiple myeloma D Ronchetti et al Y373C and K650E mutations in KMS-11 and OPM-2 cells produce activated receptors that are further stimulated by ligand binding, a ®nding that is in line with previous data showing graded FGFR3 activation in cells transfected with G380R and K650E mutations (Naski et al., 1996) . Conversely, the novel G384D mutation in KMS-18 is silent in terms of constitutive receptor activation, and the evidence that the receptor is phosphorylated following aFGF stimulation suggests that the substitution of the side-chain group of the glycine with a bulky and acidic side-chain does not aect protein activity. We found that the investigated FGFR3 mutants can modulate ERK1 and ERK2 phosphorylation, and thus the MAPK pathway: MAPK appear to be phosphorylated in all of the cell lines under starved conditions and there is an appreciable increase in phosphorylation following ligand stimulation. We cannot exclude the possibility that other FGFRs may activate MAPK in these cells, but this seems to be unlikely since FGFR1, FGFR2 and FGFR4 are not detectable in any of these cell lines, with the exception of KMS-11 which shows slight FGFR1 expression upon Northern blot analysis (data not shown). The activation of MAPK signaling by FGFR3 has been previously described in other cell systems including TD chondrocytes and NIH3T3 cells (Sahni et al., 1999) . However, activated FGFR3s in TD chondrocytes mainly seem to transduce an apoptotic signal mediated by STAT1 phosphorylation, which in turn leads to the overexpression of p21/WAF and growth arrest (Legeai-Mallet et al., 1998): we could not detect STAT1 phosphorylation in any of the cell lines under starved conditions or after ligand stimulation. It has recently been reported that the IL-6 dependent B9 murine myeloma cell line becomes IL-6 independent and shows a proliferative response when it expresses TD-mutated FGFR3 or high level of the wild-type receptor: this seemed to be mainly achieved through an anti-apoptotic pathway due to FGFR3-induced STAT3 activation, which in turn leads to the overexpression of BCL-X L (Plowright et al., 2000) . In our study, we found STAT3 phosphorylation only in the KMS-11 cell line, but the levels of phosphorylation did not seem to be modulated by ligand stimulation. On the basis of these results, we suggest that deregulated FGFR3 mutants in MM cell lines mainly activate the MAPK pathway, although we cannot exclude the possibility that other transduction pathways may be activated by FGFR3, probably depending on their cytokine dependence. All of the FGFR3 mutations investigated in our study are capable of inducing MAPK, STAT1 and STAT3 phosphorylation in transfected 293T cells, thus supporting the idea that dierent signal transduction pathways may be induced by FGFR3 activation depending on the cell system investigated. Interestingly, these data also demonstrate that, albeit in a particular experimental system, the novel G384D mutation is sucient to activate signaling cascades in a ligandindependent manner. As already suggested, one possible explanation for this experimental ®nding, which is in contrast with that observed in KMS-18 cells, could be that distinct FGFR3 mutations may lead to dierent levels of receptor activation. It is very likely that G384D is a weak mutation in vivo but fully activating when assayed under particular experimental conditions, a hypothesis that is further supported by the data from the transformation assay (see below).
A major point concerning the involvement of FGFR3 in MM is its role in the transformation process. Previous experimental evidence indicates that wild-type FGFR3 has little or no transforming ability, and it has been reported that the activated K650E FGFR3 mutant acquires transforming activity in ®broblasts only if deleted of the transmembrane and extracellular domains that are thought to regulate negatively the activity of the kinase domain (Webster and Donoghue, 1997b) . Moreover, TDI mutants have been found to be active in transformation only in FGFR3/Neu chimeric constructs in which the extracellular domain of the receptor is linked to the transmembrane and kinases domains of Neu (d'Avis et al., 1998), and it has been claimed in an abstract by Li et al. (1998) that FGFR3 carrying a mutated kinase domain has transforming activity. In our study, we found that the Y373C and (at a lower level of eciency) K650E mutations, but not the G384D mutation or the wild-type receptor, are capable of inducing foci formation in NIH3T3 cells. It should be noted that, under our experimental conditions, the eciency of transformation was relatively low when compared with that of the c-trk oncogene used as a positive control, and that the expression of the FGFR3 mutants in the transformed ®broblasts (as well as in antibiotic-resistant clones) was relatively high when compared with their respective MM cell lines (Figure 7 ). Our data con®rm that constitutively expressed wild-type FGFR3 have no transforming ability in vitro, and suggest that activating mutations in deregulated FGFR3 gene may play a critical role in the tumor progression of MM patients carrying the t(4;14) translocation.
Materials and methods
Cell lines
The KMS-11, KMS-12 and KMS-18 cell lines have been previously described (Namba et al., 1989; Otsuki et al., 1998) ; the NCI-H929 and OPM-2 cell lines were obtained from DSMZ (Braunschweig, Germany); the U266 cell line was obtained from the American Type Culture Collection (Rockville, MD, USA). The cell lines were cultured at 378C in a humidi®ed atmosphere containing 5% CO 2 , and maintained in Iscove's Modi®ed Dulbecco's Medium (IMDM) supplemented with 10% fetal calf serum (FCS). Mouse NIH3T3 ®broblasts and human embryonal kidney 293T cell line were maintained in Dulbecco's Modi®ed Eagle's Medium (DMEM) supplemented with 10% FCS, and cultured at 378C in a humidi®ed atmosphere containing respectively 10% and 5% CO 2 .
RNA analysis by Northern blot hybridization
Total RNA was prepared using the guanidine thiocyanate method. Northern blot analysis was performed according to established procedures (Sambrook et al., 1989) , using the FGFR3 full-length cDNA probe.
PCR ± SSCP and sequencing analysis
The PCR ± SSCP analysis was performed as previously described (Fracchiolla et al., 1998 ) using a non-isotopic silver staining method. The PCR-ampli®ed DNA fragments were directly sequenced using the appropriate primers. The fragments were puri®ed by means of agarose gel extraction and sequenced in both directions using the Big Dye Terminator Cycle Sequencing Kit in an ABI Prism 310 automated sequencer (Perkin Elmer). The primers used for the ampli®cations and for direct sequencing were: DT5 5'-AGGAGCTGGTGGAGGCTGAC-3', DT3 5'-GGA-GATCTTGTGCACGGTGG-3' (Fracchiolla et al., 1998) ; UF2 5'-TGGAGTTCCACTGCAAGGTGTA-3' (Murgue et al., 1994) .
Immunofluorescence analysis
The MM cell lines were ®xed in 3% paraformaldehyde-PBS, permeabilized with 0,5% TritonX-100/PBS, and subjected to indirect immuno¯uorescence using FGFR3 carboxyl-terminal antiserum (Santa Cruz Biotechnology) diluted 1 : 500, followed by¯uorescein-conjugated goat anti-rabbit secondary antibody (Boehringer).
Immunoprecipitation and Western blotting analysis
The cells were rinsed twice with PBS, and lysed on ice in PLCLB buer (50 mM HEPES, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM EGTA, 10 mM Na 4 P 2 O 7 , 100 mM NaF, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl uoride, 1 mM Na-orthovanadate). For anti-FGFR3 immunoprecipitation, protein A-sepharose was incubated with FGFR3 carboxyl-terminal antiserum (Santa Cruz Biotechnology) for 30 min, and the cell lysates were then added for 1 h. The samples were washed three times with HNTG buer (20 mM HEPES, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 10 mg/ml aprotinin, 10 mg/ml pepstatin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl¯uoride, 1 mM Naorthovanadate) and then boiled in reducing sample buer. The immunoprecipitates were electrophoresed through a 7.5% SDS ± PAGE gel and transferred to nitrocellulose. The ®lters were incubated with phosphotyrosine antiserum (mAb py99, Santa Cruz Biotechnology) followed by horseradish peroxidase-conjugated goat anti-mouse IgG, or immunoblotted with FGFR3 antiserum followed by horseradish peroxidase-conjugated goat anti-rabbit IgG, and developed by means of enhanced chemiluminescence (Supersignal, PIERCE) according to the manufacturer's instructions. The analyses of MAP Kinase, STAT1 and STAT3 proteins were made on total cell lysates using the MAP Kinase Assay Kit, the STAT1 (tyr701) antibody kit or the STAT3 (tyr705) antibody kit, according to the manufacturer's instructions (New England Biolabs). The in vivo phosphorylation assay was performed in MM cell lines starved for 48 h in the absence of FCS, and incubated at 378C for 10 min with 10 ng/ml or 100 ng/ml concentrations of aFGF (R&D System) and heparin (1 mg/ml). Suramin was added at a concentration of 100 mg/ml.
FGFR3 constructs
The full-length FGFR3 cDNA (isoform IIIC) was cloned in our laboratory from a cDNA library derived from the K-562 erytroleukemic cell line (Clontech). The coding region (FGFR3-wt) was subcloned into the pRc/CMV2 expression vector (Invitrogen). Constructs with FGFR3 cDNAs carrying mutations in the TM domain (Rc/FGFR3-KMS11 Y373C, Rc/FGFR3-KMS18/IIIb G384D, and Rc/FGFR3-KMS18/ IIIc G382D) were created from the FGFR3-wt by replacing the PmlI-BglII fragment between amino acid 290 and amino acid 413 with the same fragment obtained from the KMS-11 and KMS-18 cell lines using primers UF2 and DT3. The construct containing the FGFR3 cDNA mutated in the tyrosine kinase domain (Rc/FGFR3-OPM2 K650E) was created by replacing the wild-type ScaI-BglII fragment between amino acid 603 and amino acid 686 with the same fragment obtained from the OPM2 cell line by means of RT ± PCR using the sense primer p1813 5'-AAG-GACCTGGTGTCCTGTGC-3' and the antisense primer p2156 5'-AGCTTGAAGAGCTCCTCCA-3' (the primer numbers refer to their 5' nucleotide position according to the sequence published by Keegan et al., 1991) . All of the constructs were sequenced in both directions, and FGFR3 protein expression was tested by means of indirect immunouorescence analysis of the transfected cells.
Transfections
The U266 wt and U266 Y373C transfected cell populations were generated from the U266 MM cell line by transfecting the FGFR3-wt or Rc/FGFR3-KMS11 Y373C constructs using a modi®ed electroporation method (Lombardi et al., 1987) . Brie¯y, approximately 10 7 cells were transfected with 50 mg total DNA; the voltage and capacitance were set at respectively 300 V and 250 mF and, 48 h later, permanent transfectants were selected in G418-containing medium (1 mg/ml) (Life Technologies, Inc.). For the in vivo phosphorylation assay, the U266 wt and U266 Y373C transfected cells were starved for 48 h in IMDM 0% FCS, and incubated at 378C for 10 min with a 10 ng/ml concentration of aFGF (R&D System) and heparin (1 mg/ml). The cells were rinsed and lysed on ice, and the cell lysates immunoprecipitated as described above. The 293T cell line was transfected using a modi®ed calcium phosphate transfection method (Chen and Okayama, 1987) ; 293T cells were divided 1 : 12 onto 100 mm plates and transfected when about 60% con¯uent with 5 mg total DNA. The cells were starved for 24 h in 0.2% bovine serum albumin (BSA) and then analysed.
Focus formation assays
Twenty-four hours before transfection, the NIH3T3 cells were plated at a density of 10 5 cells onto 60 mm plates and transfected with 1 mg plasmid DNA encoding each expression construct using a modi®ed calcium phosphate transfection method (Chen and Okayama, 1987) . Eighteen hours after transfection, the cells were re-fed with DMEM containing 10% calf serum. Twin plates were transfected for each construct: the one used for the transformation assay was refed 4 h later with DMEM containing 5% calf serum, and scored after 10 or 14 days for foci formation; the second was split 1 : 25 or 1 : 50 onto 100 mm plates and selected in G418 antibiotic (0.4 mg/ml) in order to determine transfection eciency. The transformed foci were analysed for FGFR3 expression by Western blot. The focus formation assay was performed in three separate experiments (duplicate plates for each construct in each experiment).
